• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受免疫抑制治疗的多发性硬化症患者血清和脑脊液中的环磷酰胺水平。

Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.

作者信息

Hommes O R, Aerts F, Bahr U, Schulten H R

出版信息

J Neurol Sci. 1983 Feb;58(2):297-303. doi: 10.1016/0022-510x(83)90224-1.

DOI:10.1016/0022-510x(83)90224-1
PMID:6834081
Abstract

The cyclophosphamide content of urine, serum and spinal fluid of immuno-suppressed multiple sclerosis patients was determined using a newly developed off-line combination of high pressure liquid chromatography and field desorption mass spectrometry. Although urinary excretion of the drug varied considerably between patients, the levels in serum and spinal fluid were in the same range, a relationship that may facilitate control of the dosage.

摘要

采用新开发的高压液相色谱与场解吸质谱联用离线分析法,测定了免疫抑制的多发性硬化症患者尿液、血清和脑脊液中的环磷酰胺含量。尽管患者之间药物的尿排泄量差异很大,但血清和脑脊液中的含量处于同一范围,这种关系可能有助于控制剂量。

相似文献

1
Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.接受免疫抑制治疗的多发性硬化症患者血清和脑脊液中的环磷酰胺水平。
J Neurol Sci. 1983 Feb;58(2):297-303. doi: 10.1016/0022-510x(83)90224-1.
2
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.用环磷酰胺和泼尼松联合治疗慢性进行性多发性硬化症。
Clin Neurol Neurosurg. 1975;78(1):59-72. doi: 10.1016/s0303-8467(75)80007-2.
3
Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.强化免疫抑制对慢性进行性多发性硬化病程的影响。
J Neurol. 1980;223(3):177-90. doi: 10.1007/BF00313182.
4
Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry.采用场解吸质谱法测定多发性硬化症患者尿液、血清和脑脊液中的环磷酰胺。
Clin Chim Acta. 1980 Apr 25;103(2):183-92. doi: 10.1016/0009-8981(80)90212-0.
5
Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression.与环磷酰胺诱导的免疫抑制相关的自发性免疫球蛋白分泌增加。
J Clin Immunol. 1987 Mar;7(2):107-13. doi: 10.1007/BF00916004.
6
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.免疫抑制治疗对慢性进展性多发性硬化症脑脊液髓鞘碱性蛋白的短期影响。
J Neurol Neurosurg Psychiatry. 1988 Oct;51(10):1334-7. doi: 10.1136/jnnp.51.10.1334.
7
Isolation, identification and determination of cyclophosphamide and two of its metabolites in urine of a multiple sclerosis patient by high pressure liquid chromatography and field desorption mass spectrometry.
Biomed Mass Spectrom. 1981 Nov;8(11):553-7. doi: 10.1002/bms.1200081106.
8
Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid.
Acta Neurol Scand. 1989 Jan;79(1):12-7. doi: 10.1111/j.1600-0404.1989.tb03702.x.
9
Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.环磷酰胺对多发性硬化症患者免疫抑制作用的评估。
Clin Exp Immunol. 1982 Dec;50(3):495-502.
10
[Cyclophosphamide changes oligoclonal immunoglobulin G spectrum in cerebrospinal fluid in slowly progressing multiple sclerosis].[环磷酰胺改变缓慢进展型多发性硬化症患者脑脊液中的寡克隆免疫球蛋白G谱]
Neurol Neurochir Pol. 1996 Jan-Feb;30(1):7-16.

引用本文的文献

1
Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.病例报告:大剂量环磷酰胺挽救治疗后,奥瑞珠单抗成功稳定马尔堡变异型多发性硬化症病情
Front Neurol. 2021 Jun 23;12:696807. doi: 10.3389/fneur.2021.696807. eCollection 2021.
2
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.鞘内IgG合成:未来多发性硬化症治疗中一个持久且有价值的靶点。
Mult Scler Int. 2015;2015:296184. doi: 10.1155/2015/296184. Epub 2015 Jan 8.
3
Role of immunosuppressive therapy for the treatment of multiple sclerosis.
免疫抑制疗法在多发性硬化治疗中的作用。
Neurotherapeutics. 2013 Jan;10(1):77-88. doi: 10.1007/s13311-012-0172-3.
4
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.大剂量环磷酰胺诱导缓解后用醋酸格拉替雷维持治疗复发性缓解型多发性硬化症。
Mult Scler. 2012 Feb;18(2):202-9. doi: 10.1177/1352458511419701. Epub 2011 Aug 24.
5
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.环磷酰胺治疗多发性硬化症的利弊
Autoimmune Dis. 2011 Mar 15;2011:961702. doi: 10.4061/2011/961702.
6
High-dose chemotherapy and multiple sclerosis.大剂量化疗与多发性硬化。
Curr Opin Oncol. 2011 Mar;23(2):221-6. doi: 10.1097/CCO.0b013e328342c6b3.
7
Metabolism and pharmacokinetics of oxazaphosphorines.恶唑磷类化合物的代谢与药代动力学
Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.
8
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 1991 Mar;20(3):194-208. doi: 10.2165/00003088-199120030-00002.